 CAMBRIDGE, Mass., Nov. 23, 2020 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020. 